Teresa Hastings - Publications

University of Pittsburgh, Pittsburgh, PA, United States 
Neuroscience Biology, Pathology

51 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Bucher ML, Barrett CW, Moon CJ, Mortimer AD, Burton EA, Greenamyre JT, Hastings TG. Acquired dysregulation of dopamine homeostasis reproduces features of Parkinson's disease. Npj Parkinson's Disease. 6: 34. PMID 33298952 DOI: 10.1038/s41531-020-00134-x  0.92
2020 Van Laar VS, Chen J, Zharikov AD, Bai Q, Di Maio R, Dukes AA, Hastings TG, Watkins SC, Greenamyre JT, St Croix CM, Burton EA. α-Synuclein amplifies cytoplasmic peroxide flux and oxidative stress provoked by mitochondrial inhibitors in CNS dopaminergic neurons in vivo. Redox Biology. 37: 101695. PMID 32905883 DOI: 10.1016/j.redox.2020.101695  0.92
2019 Rocha EM, De Miranda BR, Castro S, Drolet R, Hatcher NG, Yao L, Smith SM, Keeney MT, Di Maio R, Kofler J, Hastings TG, Greenamyre JT. LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease. Neurobiology of Disease. 104626. PMID 31618685 DOI: 10.1016/j.nbd.2019.104626  0.32
2018 Van Laar VS, Otero PA, Hastings TG, Berman SB. Potential Role of Mic60/Mitofilin in Parkinson's Disease. Frontiers in Neuroscience. 12: 898. PMID 30740041 DOI: 10.3389/fnins.2018.00898  0.72
2018 Di Maio R, Hoffman EK, Rocha EM, Keeney MT, Sanders LH, De Miranda BR, Zharikov A, Van Laar A, Stepan AF, Lanz TA, Kofler JK, Burton EA, Alessi DR, Hastings TG, Greenamyre JT. LRRK2 activation in idiopathic Parkinson's disease. Science Translational Medicine. 10. PMID 30045977 DOI: 10.1126/scitranslmed.aar5429  0.32
2016 Di Maio R, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, Hu X, McCoy J, Chu CT, Burton EA, Hastings TG, Greenamyre JT. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. Science Translational Medicine. 8: 342ra78. PMID 27280685 DOI: 10.1126/scitranslmed.aaf3634  0.32
2016 Van Laar VS, Berman SB, Hastings TG. Mic60/mitofilin overexpression alters mitochondrial dynamics and attenuates vulnerability of dopaminergic cells to dopamine and rotenone. Neurobiology of Disease. 91: 247-61. PMID 27001148 DOI: 10.1016/j.nbd.2016.03.015  1
2015 Zharikov AD, Cannon JR, Tapias V, Bai Q, Horowitz MP, Shah V, El Ayadi A, Hastings TG, Greenamyre JT, Burton EA. shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. The Journal of Clinical Investigation. PMID 26075822 DOI: 10.1172/JCI64502  1
2013 Hauser DN, Dukes AA, Mortimer AD, Hastings TG. Dopamine quinone modifies and decreases the abundance of the mitochondrial selenoprotein glutathione peroxidase 4. Free Radical Biology & Medicine. 65: 419-27. PMID 23816523 DOI: 10.1016/j.freeradbiomed.2013.06.030  1
2013 Hauser DN, Hastings TG. Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism Neurobiology of Disease. 51: 35-42. PMID 23064436 DOI: 10.1016/j.nbd.2012.10.011  1
2013 Hauser DN, Dukes AA, Mortimer AD, Hastings TG. Dopamine quinone modifies and decreases the abundance of the mitochondrial selenoprotein glutathione peroxidase 4 Free Radical Biology and Medicine. 65: 419-427. DOI: 10.1016/j.freeradbiomed.2013.06.030  1
2013 Hastings TG, Mortimer A, Hauser D. Dopamine Oxidation and Quinone Modification of Proteins: Mechanisms of Toxicity and Implications for Parkinson's Disease Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 122. DOI: 10.1016/B978-0-12-800044-1.00105-7  1
2011 Hu X, Weng Z, Chu CT, Zhang L, Cao G, Gao Y, Signore A, Zhu J, Hastings T, Greenamyre JT, Chen J. Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 247-61. PMID 21209210 DOI: 10.1523/JNEUROSCI.4589-10.2011  1
2009 Hastings TG. The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease. Journal of Bioenergetics and Biomembranes. 41: 469-72. PMID 19967436 DOI: 10.1007/s10863-009-9257-z  1
2009 Devinney MJ, Malaiyandi LM, Vergun O, DeFranco DB, Hastings TG, Dineley KE. A comparison of Zn2+- and Ca2+-triggered depolarization of liver mitochondria reveals no evidence of Zn2+-induced permeability transition. Cell Calcium. 45: 447-55. PMID 19349076 DOI: 10.1016/j.ceca.2009.03.002  1
2009 Van Laar VS, Mishizen AJ, Cascio M, Hastings TG. Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiology of Disease. 34: 487-500. PMID 19332121 DOI: 10.1016/j.nbd.2009.03.004  1
2008 Dukes AA, Van Laar VS, Cascio M, Hastings TG. Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine. Journal of Neurochemistry. 106: 333-46. PMID 18384645 DOI: 10.1111/j.1471-4159.2008.05392.x  1
2008 Van Laar VS, Dukes AA, Cascio M, Hastings TG. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiology of Disease. 29: 477-89. PMID 18226537 DOI: 10.1016/j.nbd.2007.11.007  1
2008 Chen L, Ding Y, Cagniard B, Van Laar AD, Mortimer A, Chi W, Hastings TG, Kang UJ, Zhuang X. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 425-33. PMID 18184785 DOI: 10.1523/JNEUROSCI.3602-07.2008  1
2007 Weng Z, Signore AP, Gao Y, Wang S, Zhang F, Hastings T, Yin XM, Chen J. Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling. The Journal of Biological Chemistry. 282: 34479-91. PMID 17895242 DOI: 10.1074/jbc.M705426200  1
2007 Venneti S, Lopresti BJ, Wang G, Slagel SL, Mason NS, Mathis CA, Fischer ML, Larsen NJ, Mortimer AD, Hastings TG, Smith AD, Zigmond MJ, Suhara T, Higuchi M, Wiley CA. A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation. Journal of Neurochemistry. 102: 2118-31. PMID 17555551 DOI: 10.1111/j.1471-4159.2007.04690.x  1
2006 Tehranian R, Montoya SE, Van Laar AD, Hastings TG, Perez RG. Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. Journal of Neurochemistry. 99: 1188-96. PMID 16981894 DOI: 10.1111/j.1471-4159.2006.04146.x  1
2006 Signore AP, Weng Z, Hastings T, Van Laar AD, Liang Q, Lee YJ, Chen J. Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death. Journal of Neurochemistry. 96: 428-43. PMID 16336625 DOI: 10.1111/j.1471-4159.2005.03587.x  1
2005 Liang Q, Smith AD, Pan S, Tyurin VA, Kagan VE, Hastings TG, Schor NF. Neuroprotective effects of TEMPOL in central and peripheral nervous system models of Parkinson's disease Biochemical Pharmacology. 70: 1371-1381. PMID 16144694 DOI: 10.1016/j.bcp.2005.04.011  1
2005 Dukes AA, Korwek KM, Hastings TG. The effect of endogenous dopamine in rotenone-induced toxicity in PC12 cells. Antioxidants & Redox Signaling. 7: 630-8. PMID 15890007 DOI: 10.1089/ars.2005.7.630  1
2004 Perez RG, Hastings TG. Could a loss of alpha-synuclein function put dopaminergic neurons at risk? Journal of Neurochemistry. 89: 1318-24. PMID 15189334 DOI: 10.1111/j.1471-4159.2004.02423.x  1
2004 Kim SI, Voshol H, van Oostrum J, Hastings TG, Cascio M, Glucksman MJ. Neuroproteomics: expression profiling of the brain's proteomes in health and disease. Neurochemical Research. 29: 1317-31. PMID 15176488 DOI: 10.1023/B:NERE.0000023618.35579.7c  1
2004 Greenamyre JT, Hastings TG. Biomedicine. Parkinson's--divergent causes, convergent mechanisms. Science (New York, N.Y.). 304: 1120-2. PMID 15155938 DOI: 10.1126/science.1098966  1
2004 LaVoie MJ, Card JP, Hastings TG. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Experimental Neurology. 187: 47-57. PMID 15081587 DOI: 10.1016/j.expneurol.2004.01.010  1
2002 Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 8951-60. PMID 12388602  1
2002 Zigmond MJ, Hastings TG, Perez RG. Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Parkinsonism & Related Disorders. 8: 389-93. PMID 12217625 DOI: 10.1016/S1353-8020(02)00019-6  1
2002 Chen D, Cao G, Hastings T, Feng Y, Pei W, O'Horo C, Chen J. Age-dependent decline of DNA repair activity for oxidative lesions in rat brain mitochondria. Journal of Neurochemistry. 81: 1273-84. PMID 12068075 DOI: 10.1046/j.1471-4159.2002.00916.x  1
2000 Rabinovic AD, Lewis DA, Hastings TG. Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience. 101: 67-76. PMID 11068137 DOI: 10.1016/S0306-4522(00)00293-1  1
2000 Berman SB, Watkins SC, Hastings TG. Quantitative biochemical and ultrastructural comparison of mitochondrial permeability transition in isolated brain and liver mitochondria: Evidence for reduced sensitivity of brain mitochondria Experimental Neurology. 164: 415-425. PMID 10915580 DOI: 10.1006/exnr.2000.7438  1
1999 LaVoie MJ, Hastings TG. Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss. Journal of Neurochemistry. 73: 2546-54. PMID 10582617 DOI: 10.1046/j.1471-4159.1999.0732546.x  1
1999 Berman SB, Hastings TG. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implications for Parkinson's disease Journal of Neurochemistry. 73: 1127-1137. PMID 10461904 DOI: 10.1046/j.1471-4159.1999.0731127.x  1
1999 Stokes AH, Hastings TG, Vrana KE. Cytotoxic and genotoxic potential of dopamine. Journal of Neuroscience Research. 55: 659-65. PMID 10220107 DOI: 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C  1
1999 LaVoie MJ, Hastings TG. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 1484-91. PMID 9952424  1
1998 Rabinovic AD, Hastings TG. Role of endogenous glutathione in the oxidation of dopamine. Journal of Neurochemistry. 71: 2071-8. PMID 9798932  1
1998 Zigmond MJ, Hastings TG. Neurochemical responses to lesions of dopaminergic neurons: implications for compensation and neuropathology. Advances in Pharmacology (San Diego, Calif.). 42: 788-92. PMID 9328016 DOI: 10.1016/S1054-3589(08)60865-0  1
1997 Berman SB, Hastings TG. Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species Journal of Neurochemistry. 69: 1185-1195. PMID 9282942  1
1997 Hastings TG, Zigmond MJ. Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. Journal of Neural Transmission. Supplementum. 49: 103-10. PMID 9266419  1
1997 Hoyt KR, Reynolds IJ, Hastings TG. Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamate-induced cell death. Experimental Neurology. 143: 269-81. PMID 9056389 DOI: 10.1006/exnr.1996.6374  1
1997 Hoyt KR, Gallagher AJ, Hastings TG, Reynolds IJ. Characterization of hydrogen peroxide toxicity in cultured rat forebrain neurons. Neurochemical Research. 22: 333-40. PMID 9051670 DOI: 10.1023/A:1022403224901  1
1996 Hastings TG, Lewis DA, Zigmond MJ. Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Advances in Experimental Medicine and Biology. 387: 97-106. PMID 8794199 DOI: 10.1007/978-1-4757-9480-9_13  1
1996 Berman SB, Zigmond MJ, Hastings TG. Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. Journal of Neurochemistry. 67: 593-600. PMID 8764584  1
1996 Hastings TG, Lewis DA, Zigmond MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proceedings of the National Academy of Sciences of the United States of America. 93: 1956-61. PMID 8700866 DOI: 10.1073/pnas.93.5.1956  1
1995 Giovanni A, Liang LP, Hastings TG, Zigmond MJ. Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. Journal of Neurochemistry. 64: 1819-25. PMID 7891110 DOI: 10.1046/j.1471-4159.1995.64041819.x  1
1995 Hastings TG. Enzymatic oxidation of dopamine: The role of prostaglandin H synthase Journal of Neurochemistry. 64: 919-924. PMID 7830086  1
1994 Hastings TG, Zigmond MJ. Identification of catechol-protein conjugates in neostriatal slices incubated with [3H]dopamine: impact of ascorbic acid and glutathione. Journal of Neurochemistry. 63: 1126-32. PMID 8051554 DOI: 10.1046/j.1471-4159.1994.63031126.x  1
1992 Zigmond MJ, Hastings TG, Abercrombie ED. Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease. Annals of the New York Academy of Sciences. 648: 71-86. PMID 1637074 DOI: 10.1111/j.1749-6632.1992.tb24525.x  1
Show low-probability matches.